Rheumatoid arthritis treatment;Tratamiento de la artritis reumatoide

Revista Clinica Espanola

Volumn 204, Issue 5, 2004, Pages 273-282

  Mulero Mendoza, J ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ADALIMUMAB; AZATHIOPRINE; CELECOXIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DICLOFENAC; DIFLUNISAL; ETANERCEPT; FLURBIPROFEN; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMATE SODIUM; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PIROXICAM; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; SULINDAC; TENOXICAM; TOLMETIN; UNINDEXED DRUG;

BLOOD TOXICITY; CLINICAL FEATURE; DISEASE EXACERBATION; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; IMMUNOTOXICITY; INFECTION; LEUKOPENIA; NEUROTOXICITY; NEUTROPENIA; PREVALENCE; PROGNOSIS; RENOVASCULAR HYPERTENSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

EID: 2942543213     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13061416     Document Type: Review

References (75)

1. Carmona L, Villaverde V, Hernández-García C, Ballina J, Gabriel R, Laffon A. EPISER Study Group. The prevalence of rheumatoid artritis in the general population of Spain. Rheumatology 2002;41:88-95.
2. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
3. Prior P, Symmons DP, Scott DL, Brown R, Hawkins CF. Cause of death in rheumatoid arthritis. Br J Rheumatol 1984;23:92-9.
4. Rieemsma RP, Kirwan JR, Taal E, Rasker JJ. Patient education for adults with rheumatoid arthritis. Cochrane Database Syst Rev 2002;2: CD003688.
5. Grupo GUIPCAR. Guía de práctica clínica para el manejo de la artritis reumatoide en España. Sociedad Españ ola de Reumatología. Madrid, 2001.
6. Fries JF, Spitz JW, Mitchell DM, Roth SH, Wolfe F, Bloch DA. Impact of specific therapy upon rheumatoid arthritis. Arthritis Rheum 1986;29: 620-7.
7. Abu-Shakra M, Toser R, Flusser D, Flusser G, Friger M, Sukenik S, et al. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs. Autoimmunity 1998;41:1190-5.
8. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
9. Moreland LW, Bridges SL Jr. Early rheumatoid arthritis: a medical emergency? Am J Med 2001;111:498-500.
10. Emery P. Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol 2002;29(Suppl 66):3-8.
11. Kim J, Weisman M. When does rheumatoid arthritis begin and why do we need to know? Arthritis Rheum 2000;43:473-84.
12. Chan K-WA, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994; 37:814-20.
13. Harrison BJ, Symmons DP, Brennan P, Barrett EM, Silman AJ. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996;35:1096-100.
14. Van der Heijde DM, van Riel PL, van Leeuwen MA, et al. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective followup study of 147 patients. Br J Rheumatol 1992;31:519-25.
15. Machold KP, Eberl G, Leeb BF, Nell V, Vindisch B, Smolen JS. Early arthritis therapy: rationale and current approach. J Rheumatol 1998;25 (Suppl 53):13-9.
16. American College of Rheumatology subcommittee on rheumatoid arthritis guidelines. Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum 2002;46:328-46.
17. Esteve-Vives J, Batlle-Gualda E, Reig A. Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency. Grupo para la Adaptación del HAQ a la Población Española. J Rheumatol 1993;20(12):2116-22.
18. Ostegaard M, Szkudlarek M. Imaging in rheumatoid artritis-why MRI and ultrasonography can no longer be ignored. Scand J Rheumatol 2003; 32:63-73.
19. Van Riel PLCM. Provisional guidelines for measuring disease activity in RA clinical trials. Br J Rheumatol 1992;31:793-4.
20. Lanas A, Martín-Mola E, Ponce J, Navarro F, Piqué JM, Blanco FJ. Estrategia clínica para la prevención de los efectos adversos sobre el tracto digestivo de los antiinflamatorios no esteroideos. Rev Esp Reumatol 2003; 30:393-410.
21. Singh G, Triadafilopoulus G. Epidemiology of NSAID-induced gastrointestinal complications. J Rheumatol (Suppl)1999;26:18-24.
22. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroideal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
23. Chan FKL, Hung LCT, Suen B Y, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.
24. Bijlsma JWJ, Borres M, Saag KG, Furst DE. Glucocorticoids in the treatment of early and lagte RA. Ann Rheum Dis 2003;62:1033-7.
25. Svensson B, Albertsson K, Boonen A, et al. The clinical efficacy of low dose prednisolone in addition to DMARDS in early, active RA: an open randomized study. Arthritis Rheum 2003;48(Suppl):S652.
26. Porter DR, Grigor C, Stirling A, et al. A randomised controlled trial of a strategy of tight control of disease activity in rheumatoid artritis-outcome over 18 months. Arthritis Rheum 2003;48(Suppl);S232.
27. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
28. Verstappen SMM, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003;48:1797-807.
29. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid artritis. N Engl J Med 1985;312:818-22.
30. Suárez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for treating rheumatoid arthritis (cochrane review). The cochrane library. Issue 4. Oxford: Update Software, 2001.
31. Tugwell P, Bombardier C, Buchanan WW, Goldsmith C, Grace F, Bennett KJ, et al. Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard item and individualized patient preference health status questionnaires. Arch Intern Med 1990;150:59-62.
32. Drosos AA, Tsifetaki N, Tsiakou EK, Timpanidou M, Tsampoulas C, Tatsis CK, et al. Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Clin Exp Rheumatol 1997;15:263-7.
33. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-7.
34. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992;35:138-45.
35. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al Methotrexate in rheumatoid artritis: a five-year prospective multicenter study. Arthritis Rheum 1994;37:1492-8.
36. González-Álvaro I, Carmona L, Balsa A, Sanmarti R, Belmonte MA, Tena X. EMECAR Study Group. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 2003;30:697-704.
37. Van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma CJ, Thomas CM, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002;41:658-65.
38. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.
39. Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.
40. Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate, etanercept, infliximab and anakinra-associated adverse events. Arthritis Rheum 2003;48:2769-72.
41. Cartwright VW, Michaud K, Choi HK, Wolfe F. Methotrexate laboratory testing and risk of serious illness: analyses in 20,000 patients. Arthritis Rheum 2003;48(Suppl):S428.
42. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology 2003;42:6-13.
43. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002;41:1346-56.
44. Rau R. Combination DMARD treatment with parenteral gold and methotrexate. Clin Exp Rheumatol 1999;17(Suppl):S83-90.
45. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
46. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology 2000;39:975-81.
47. Riise T, Jacobsen BK, Gran JT. Changes in therapy of rheumatoid arthritis during the period 1979 to 1996. Scand J Rheumatol 2001;30: 199-202.
48. Sanmarti R, Gómez A, Ercilla G, Gratacos J, Larrosa M, Suris X, et al. Radiological progression in early rheumatoid arthritis after DMARDS: a one-year follow-up study in a clinical setting. Rheumatology 2003;42: 1044-9.
49. Osiri M, Shea B, Robinson V, Suárez-Almazor M, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003;30:1182-90.
50. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603.
51. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind randomised, multicentre trial Lancet 1999;353:259-66.
52. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I on behalf of the leflunomide Rheumatoid Artritis investigators Group. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000;43:495-505.
53. Emery P, Breeveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. J Rheumatol 2000;39:655-65.
54. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999;42:1870-8.
55. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003;62:944-51.
56. Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003; 48:1513-20.
57. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
58. Genovese MC, Bathon JM, Martín RW, et al. Etanercept versus methotrexate in patients with early rheumatoid artritis. Two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
59. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
60. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
61. Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2003;(4):CD004525.
62. Lipsky PE, van der Heijde DMFM, Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343:1594-1602.
63. Bresnihan B, Cobby M.Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology 2003;42(Suppl 2):ii22-8.
64. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii13-6.
65. Ang HTS, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-a antangonists in patients with rheumatoid arthritis?
66. Comité científico de Biobadaser. BIOBADASER: informe de situación semestral. Rev Esp Reumatol 2003;30:119-23.
67. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasnznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
68. Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol 2002;20(Suppl 28):S152-S7.
69. Salaffi F, Carotti M, Cervini C. Combination therapy of cyclosporine: a with methotrexate or hydroxycholoroquine in refractory rheumatoid arthritis. Scand J Rheumatol 1996;25:16-23.
70. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
71. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
72. Möttonen T, Hannonen P, Leirisalo-Repo M, Nissita M, Kautianen H, Korpela M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 1999;353: 1568-73.
73. Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli I, et al. Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 1999;17:699-704.
74. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
75. Actualización del consenso de la Sociedad Española de Reumatología sobre la terapia con agentes inhibidores del TNF en la artritis reumatoide. Rev Esp Reumatol 2002;29:51-5.